DNLI
Denali Therapeutics Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 97 | +6 | 103.66M | $2.65B | +11 | −4 |
| Q1 2026 | 93 | +4 | 96.77M | $1.85B | +11 | −8 |
| Q4 2025 | 89 | 0 | 110.68M | $1.83B | +1 | — |
| Q3 2025 | 19 | 0 | 67.26M | $976.61M | — | −1 |
| Q2 2025 | 17 | +1 | 74.76M | $1.05B | +2 | −1 |
| Q1 2025 | 13 | +1 | 44.98M | $611.55M | +2 | −1 |
| Q4 2024 | 12 | -1 | 38.31M | $780.78M | — | −1 |
| Q3 2024 | 12 | 0 | 34.10M | $993.27M | +1 | −1 |
| Q2 2024 | 12 | — | 35.56M | $825.78M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Baillie Gifford ✦ | 13.76M | — | $319.59M | 0.2% | n/c | 1 | SEC ↗ |
| 2 | Baillie Gifford ✦ | 13.76M | — | $319.59M | 0.2% | n/c | 1 | SEC ↗ |
| 3 | Baillie Gifford ✦ | 13.76M | — | $319.59M | 0.2% | n/c | 1 | SEC ↗ |
| 4 | Baillie Gifford ✦ | 13.76M | — | $319.59M | 0.2% | n/c | 1 | SEC ↗ |
| 5 | Wellington Management ✦ | 9.82M | — | $228.11M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Wellington Management ✦ | 9.82M | — | $228.11M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Wellington Management ✦ | 9.82M | — | $228.11M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Wellington Management ✦ | 9.82M | — | $228.11M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Wellington Management ✦ | 9.82M | — | $228.11M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Wellington Management ✦ | 9.82M | — | $228.11M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Wellington Management ✦ | 9.82M | — | $228.11M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Geode Capital Management ✦ (passive) | 2.98M | — | $69.27M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Geode Capital Management ✦ (passive) | 2.98M | — | $69.27M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | Marshall Wace ✦ | 2.42M | — | $56.17M | 0.1% | n/c | 1 | SEC ↗ |
| 15 | T. Rowe Price ✦ | 2.26M | — | $52.37M | 0.0% | n/c | 1 | SEC ↗ |
| 16 | T. Rowe Price ✦ | 2.26M | — | $52.37M | 0.0% | n/c | 1 | SEC ↗ |
| 17 | Citadel Advisors ✦ | 1.22M | — | $28.30M | 0.0% | n/c | 1 | SEC ↗ |
| 18 | Point72 Asset Management ✦ | 1.05M | — | $24.45M | 0.1% | n/c | 1 | SEC ↗ |
| 19 | Norges Bank ✦ (passive) | 823.94K | — | $19.13M | 0.0% | n/c | 1 | SEC ↗ |
| 20 | Millennium Management ✦ | 619.93K | — | $14.39M | 0.0% | n/c | 1 | SEC ↗ |
| 21 | Fisher Asset Management ✦ | 478.11K | — | $11.10M | 0.0% | n/c | 1 | SEC ↗ |
| 22 | Two Sigma Investments ✦ | 94.87K | — | $2.20M | 0.0% | n/c | 1 | SEC ↗ |
| 23 | D. E. Shaw & Co. ✦ | 29.72K | — | $690,122 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 265 holders, 147.10M shares, $2.60B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 2.86K sh · $71,625
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology